Market News & Trends
New Preclinical Studies Reinforce the Potential for Heightened Anti-Cancer Activity of Combination Therapies Based on Immunovaccine’s Proprietary Delivery Platform
Immunovaccine Inc. recently announced that it presented new research on its T-cell activating platform at the American Association for Cancer Research (AACR) Annual Meeting 2018.…
Organovo Achieves Key Development Milestones
Organovo Holdings, Inc. recently announced that along with its collaborators, it has achieved several breakthrough capabilities for its 3D bioprinted tissues. At the International Liver Congress,…
Kineta to Collaborate on the Development of a Novel Non-Opioid Pain Therapy With Genentech
Kineta Chronic Pain, LLC, a subsidiary of Kineta, Inc., recently announced it has entered into an exclusive option and license agreement with Genentech, a member…
Foamix Announces $16 Million Investment by OrbiMed
Foamix Pharmaceuticals Ltd. recently announced it has raised aggregate gross proceeds of approximately $16 million through a direct registered offering of its ordinary shares to OrbiMed. On…
Synteract Repositions Itself With Centers of Therapeutic Development & Unveils Updated Brand Platform
Synteract recently announced the creation of therapeutic centers of development that include some of the most progressive in the biopharma industry: oncology, especially leading-edge immunotherapy…
Carpe Secures $2.3 Million to Fight Hyperhidrosis
Carpe, a skincare startup offering over-the-counter relief for excessive hand and foot sweating to the estimated 365 million hyperhidrosis sufferers worldwide, recently announced it has…
WuXi AppTec Expands Site in the United States for Drug Development Testing Services
WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, recently announced the opening of its expanded Laboratory Testing Division…
Provectus Biopharmaceuticals Expands Global Patent Portfolio
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company developing PV-10 as the first small molecule oncolytic immunotherapy for solid tumor cancers, recently announced that the Japan Patent…
Aclaris Therapeutics Partners With Cipher Pharmaceuticals
Aclaris Therapeutics, Inc. recently announced it has licensed the Canadian rights to commercialize A-101 40% topical solution for the treatment of raised seborrheic keratoses (A-101…
BriaCell Presents Encouraging Clinical Data
BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company with a proprietary targeted immunotherapy technology, recently announced it presented a late-breaking poster presentation at the Annual Meeting…
Wave Life Sciences & Deep Genomics Form Collaboration
Wave Life Sciences Ltd. and Deep Genomics Inc. recently announced the formation of a collaboration to identify novel therapies to be developed by Wave for…
Ubiquigent & Forma Therapeutics Enter Exclusive R&D Collaboration
Ubiquigent Limited recently announced it has entered into a multi-year strategic R&D collaboration agreement with FORMA Therapeutics for the design and development of novel deubiquitylase…
Syntel Partners With Esko for Life Sciences Labeling & Packaging Solutions
Syntel, Inc. recently announced it has signed a strategic partnership with Esko, a leading provider of prepress software and hardware for labeling and packaging. Headquartered…
Nutriband Acquires 4P Therapeutics; Creates Transdermal & Topical Arm
Nutriband Inc. recently announced the acquisition of 4P Therapeutics Inc. on April 5, 2018. Nutriband has acquired 100% interest in 4P Therapeutics for a total…
Halo Pharma Simplifies Topical Drug Product Development & Manufacturing
Halo Pharma, a rapidly growing contract development and manufacturing organization (CDMO), offers more than 30 years’ direct experience in the production of topical drug products…
Argenx to Receive Third Preclinical Milestone Payment From LEO Pharma
argenx recently announced the achievement of its third preclinical milestone from its collaboration with LEO Pharma, following the approval of the clinical trial application (CTA)…
GSK Signs Strategic Agreement With Orchard Therapeutics
GSK and Orchard Therapeutics today announced a strategic agreement, under which GSK will transfer its portfolio of approved and investigational rare disease gene therapies to…
ReForm Biologics & KBI Biopharma Announce Strategic Partnership
ReForm Biologics and KBI BioPharma, Inc recently announced a strategic partnership to make improved biopharmaceutical formulations. Through this collaboration, KBI and ReForm will help customers…
XBiotech In-licenses Anti-NY-ESO-1 Antibody Targeting Advanced Cancer
XBiotech USA, Inc. recently announced it has obtained an exclusive, worldwide license from CT Atlantic AG (CTA), a Swiss biotechnology company. Under the terms of…
Retrophin Initiates Pivotal Phase 3 Clinical Trial
Retrophin, Inc. recently announced that the first patient has been enrolled in the DUPLEX Study, a global, pivotal Phase 3 clinical trial evaluating the long-term…
